Moberg Pharma: Making good progress
Research Update
2018-05-24
07:30
The development in the OTC business was solid in 1Q18 and beat our expectations in almost every aspect. With a positive development in 1Q18 and a stronger USD, we raise our forecasts and our fair value to SEK 64 (62).
KP
Klas Palin
Disclosures and disclaimers